MDM2 and in situ carcinoma: However, mutation of the SRSF1 sites in MDM2 exon 11 (174, 175 mutant minigene) eliminated the damage-responsive exon 11 skipping upon UV (MCF-7 0.270 ± 0.01958% SEM, HeLa 4.933 ± 0.3093% SEM) and cisplatinum treatment (MCF-7 2.235 ± 0.4246% SEM, HeLa 1.800 ± 0.6848% SEM) compared to the skipping of the WT minigene under UV and (MCF-7 31.200 ± 2.140% SEM, HeLa 39.227 ± 2.819% SEM) cisplatinum (MCF-7 33.935 CIS ± 1.709% SEM, HeLa 27.330 ± 0.7490% SEM) treatments (Figure 4).